Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4425980 | 0.81 | AOC3 (0.40) | OPRM1 | |
| SCHEMBL3829073 | 0.79 | OPRM1 (0.47) | OPRM1OPRL1 | |
| SCHEMBL6421263 | 0.77 | CES2 (0.32) | CES2CES1OPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL4740359 | 0.76 | AOC3 (0.39) | OPRM1 | |
| SCHEMBL6423549 | 0.75 | CES2 (0.37) | CES2CES1OPRM1OPRL1MAPT | |
| SCHEMBL29279108 | 0.73 | CHEK1 (0.40) | CES2CES1OPRM1OPRL1 | |
| SCHEMBL3825964 | 0.73 | CHRNB2 (0.46) | OPRM1KDM4EMAPTALDH1A1 | |
| SCHEMBL4432794 | 0.72 | CES2 (0.37) | CES2CES1OPRM1MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL5669807 | 0.72 | CHEK1 (0.39) | CES2CES1OPRM1OPRL1 | |
| SCHEMBL15562837 | 0.71 | ALDH1A1 (0.50) | OPRM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| US-20060142333-A1 | Vanilloid receptor modulators | MACDONALD GREGOR J | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142333-A1 | Vanilloid receptor modulators | TRPV1, NPSR1, TRPV3 | CES2 1914/4885CES1 1861/4885PDPK1 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.